Evaluation and Management of Acute Upper Respiratory Symptoms with Anosmia/Ageusia
This is most likely COVID-19 given the constellation of symptoms—particularly the loss of taste and smell—and you should test for SARS-CoV-2 immediately while providing symptomatic care and monitoring for progression.
Immediate Assessment
The symptom profile is highly suggestive of COVID-19 infection. Loss of smell (anosmia) and taste (ageusia) are strongly predictive of SARS-CoV-2 infection, with studies showing these symptoms are independently associated with COVID-19 positivity (adjusted odds ratio 10.9 for anosmia and 10.2 for ageusia) 1. In healthcare workers presenting with influenza-like symptoms, 68% of COVID-19-positive patients reported smell loss and 71% reported taste loss, compared to only 16-17% of COVID-19-negative patients 1.
Key diagnostic indicators present in this patient:
- Anosmia and ageusia (strongest predictors of COVID-19)
- Sore throat, nasal congestion, and myalgias
- 3-day symptom duration (typical early COVID-19 presentation)
- Young age (23 years) - this demographic commonly presents with central nervous system symptoms like anosmia 2
Testing Strategy
Obtain SARS-CoV-2 PCR or rapid antigen test immediately. The presence of multiple symptoms (sore throat, congestion, body aches) combined with anosmia/ageusia makes COVID-19 highly likely 3, 4. Testing for other respiratory viruses (influenza, RSV, adenovirus) can be considered if COVID-19 testing is negative and symptoms persist 5.
Treatment Approach
Symptomatic Management (Primary Treatment)
Since this is likely viral and the patient is young without mentioned comorbidities, focus on symptomatic relief 3, 6:
- Pain and fever control: Ibuprofen or paracetamol for body aches and any fever 7
- Nasal congestion: Intranasal saline irrigation is recommended 6. Topical or oral decongestants can be used short-term, though evidence is limited 8
- Adequate hydration and rest
- Sleep with head elevated
Antibiotics Are NOT Indicated
Do not prescribe antibiotics. This presentation is consistent with acute viral upper respiratory infection, not bacterial sinusitis 6. The symptoms have only been present for 3 days—well below the 10-day threshold that would suggest bacterial acute rhinosinusitis (ABRS) 6, 8.
According to evidence-based guidelines, antibiotics should only be considered for acute rhinosinusitis when 6:
- Symptoms persist >10 days without improvement, OR
- Severe symptoms (fever >39°C, purulent nasal discharge, facial pain) for ≥3 consecutive days, OR
- "Double sickening" (worsening after initial improvement)
None of these criteria are met. The sore throat similarly does not warrant antibiotics without evidence of Group A streptococcal infection 7.
Monitoring and Red Flags
Instruct the patient to monitor for progression and seek immediate care if:
- Shortness of breath or difficulty breathing develops
- Persistent chest pain or pressure
- New confusion or inability to stay awake
- Bluish lips or face
- Severe or worsening symptoms after 10 days
Most COVID-19 patients with mild disease (which this appears to be) stabilize without specific treatment 3. However, approximately 14% may deteriorate despite initial mild presentation 3.
Isolation and Prevention
The patient should isolate for at least 5 days from symptom onset and until fever-free for 24 hours without fever-reducing medications, per current public health guidance 3. Emphasize hand hygiene and avoiding close contact with others, especially those at high risk for severe disease (elderly, immunocompromised, those with chronic conditions) 3.
Prognosis for Anosmia/Ageusia
Reassure the patient that most COVID-19-associated smell and taste loss resolves within weeks, paralleling resolution of other symptoms. In one study, 74% of patients reported resolution of anosmia with clinical resolution of illness 1. However, some patients may experience persistent chemosensory dysfunction beyond 12 weeks (23.6% in one cohort) 2. If anosmia persists beyond 3 months, consider referral for olfactory training and intranasal corticosteroids 9.
Common Pitfalls to Avoid
- Do not prescribe antibiotics for viral upper respiratory symptoms - this contributes to antimicrobial resistance and exposes patients to unnecessary adverse effects 8, 6
- Do not dismiss anosmia/ageusia as trivial - these are highly specific for COVID-19 and should trigger testing 1, 4
- Do not use mucus color alone to justify antibiotics - purulent discharge reflects neutrophils, not necessarily bacteria 8
- Do not order imaging (CT, X-ray) for uncomplicated acute symptoms - clinical diagnosis is sufficient 6, 8